03.10.14
Maxx Orthopedics Inc., a subsidiary of Maxx Medical Pvt. Ltd., has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Freedom PCK components, the latest addition to its revision knee system.
The Freedom PCK combines Maxx’s previously-cleared Freedom stemmed tibial components with its femoral components and constrained liners (both awaiting patents), to create a bone conserving, low profile revision knee system.
This complete revision knee replacement system was developed to provide a wide variety of component size and stability configurations, while conserving bone. It offers a constrained option to surgeons whose patients require additional stability, reportedly without significantly compromising range of motion and rotation.
“Our design approach has always been focused on innovative size, fit and component compatibility configurations to optimize range of motion while minimizing bone loss,” said CEO Ashesh Shah. “The Freedom PCK extends this philosophy to a constrained system, with its progressive constraint design, which we believe makes it the most innovative revision knee system on the market. With the addition of the Freedom PCK, Maxx’s Freedom Total Knee portfolio takes a big leap forward in addressing the needs of surgeons and patients.”
Freedom Knee is a total knee replacement system specifically engineered for high flexion, bone conservation and advanced component size and fit capabilities. Launched in 2009, Freedom Knee received analyst group Frost & Sullivan’s “Product Differentiation Excellence Award in Orthopedic Knee Joint Replacement.” Freedom Knee has FDA, Drugs Controller General of India (DCGI), European CE mark, and State Food and Drug Administration P.R. China approvals. The system is manufactured in the United States.
Maxx Medical is based in Plymouth Meeting, Pa.
The Freedom PCK combines Maxx’s previously-cleared Freedom stemmed tibial components with its femoral components and constrained liners (both awaiting patents), to create a bone conserving, low profile revision knee system.
This complete revision knee replacement system was developed to provide a wide variety of component size and stability configurations, while conserving bone. It offers a constrained option to surgeons whose patients require additional stability, reportedly without significantly compromising range of motion and rotation.
“Our design approach has always been focused on innovative size, fit and component compatibility configurations to optimize range of motion while minimizing bone loss,” said CEO Ashesh Shah. “The Freedom PCK extends this philosophy to a constrained system, with its progressive constraint design, which we believe makes it the most innovative revision knee system on the market. With the addition of the Freedom PCK, Maxx’s Freedom Total Knee portfolio takes a big leap forward in addressing the needs of surgeons and patients.”
Freedom Knee is a total knee replacement system specifically engineered for high flexion, bone conservation and advanced component size and fit capabilities. Launched in 2009, Freedom Knee received analyst group Frost & Sullivan’s “Product Differentiation Excellence Award in Orthopedic Knee Joint Replacement.” Freedom Knee has FDA, Drugs Controller General of India (DCGI), European CE mark, and State Food and Drug Administration P.R. China approvals. The system is manufactured in the United States.
Maxx Medical is based in Plymouth Meeting, Pa.